Invited commentary: The importance of prevalence in the effectiveness of a (Bio)marker

American Journal of Epidemiology

Volumn 173, Issue 12, 2011, Pages 1388-1390

  Ghosh, Arpita ^a   Castle, Philip E ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ASCP   (United States)

Author keywords

biological markers; censored data; life change events; menopause; premenopause; survival analysis

Indexed keywords

BIOLOGICAL MARKER;

BIOMARKER; DATA INTERPRETATION; DISEASE INCIDENCE; HEALTH CARE; HEALTH IMPACT; PREDICTION; REPRODUCTIVE BIOLOGY; SURVIVAL; WOMENS HEALTH;

CLINICAL EFFECTIVENESS; FAMILY HISTORY; GENETIC MARKER; GENOTYPE; HUMAN; MENOPAUSE; MENSTRUAL CYCLE; METHODOLOGY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROSTATE CANCER; REVIEW; RISK ASSESSMENT;

BIOLOGICAL MARKERS; FEMALE; HUMANS; MENOPAUSE; MENSTRUAL CYCLE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; REPRODUCTIVE HISTORY;

EID: 79958848136     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr016     Document Type: Review

References (13)

1. Little RJ, Yosef M, Nan B, et al. A method for longitudinal prospective evaluation of markers for a subsequent event. Am J Epidemiol. 2011;173(12):1380-1387.
2. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358(9):910-919. (Pubitemid 351397090)
3. Pepe MS, Janes H, Longton G, et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol. 2004;159(9):882-890. (Pubitemid 38657490)
4. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-527. (Pubitemid 36159887)
5. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590): 890-907. (Pubitemid 47371147)
6. Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008;168(2): 123-137. (Pubitemid 351951589)
7. Castle PE, Rodríguez AC, Burk RD, et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ. 2009; 339:b2569. (doi: 10.1136/bmj.b2569).
8. National Cancer Institute. BRCA1 and BRCA2: Cancer Risk and Genetic Testing. (National Cancer Institute Fact Sheet). Bethesda, MD: National Cancer Institute; 2009. (http:// www.cancer.gov/cancertopics/factsheet/Risk/BRCA). (Accessed November 3, 2010).
9. Pepe MS, Gu JW, Morris DE. The potential of genes and other markers to inform about risk. Cancer Epidemiol Biomarkers Prev. 2010;19(3):655-665.
10. Wacholder S. The impact of a prevention effort on the community. Epidemiology. 2005;16(1):1-3. (Pubitemid 40239271)
11. Park JH,Wacholder S, Gail MH, et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet. 2010;42(7):570-575.
12. Hartge P. Genetics of reproductive lifespan. Nat Genet. 2009;41(6):637-638.
13. Solomon D, Castle P, Hildesheim A, et al. HPV vaccination in women aged 24-45 years [reply to letter]. Lancet. 2009; 374(9697):1239-1240.